Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07572383 · ClinicalTrials.gov registry record · Phase 2
Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis
A Phase 2 study, sponsored by Peter Caravan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT07572383 is a Phase 2 study that is actively recruiting participants, run by Peter Caravan. The registered enrollment target is 15 participants.
The verdict
NCT07572383, a Phase 2 study, is actively recruiting participants, sponsored by Peter Caravan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).
Interventions
- DRUG [68Ga]CBP8
- DRUG Gadoterate Meglumine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-04 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07572383
The ClinicalTrials.gov registry entry for NCT07572383 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peter Caravan, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [68Ga]CBP8 is the first listed.
NCT07572383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07572383 about?
NCT07572383 is a clinical study titled "Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis". The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopath...
What is the current status of trial NCT07572383?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2026-04. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07572383?
The interventions under investigation include: [68Ga]CBP8 (DRUG), Gadoterate Meglumine (DRUG).
Who is sponsoring clinical trial NCT07572383?
This trial is sponsored by Peter Caravan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.